Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis

Inclusion Criteria:

* 18 \< age \< 70 man or woman
* Patient with a cytologically or histologically proven primary solid tumor
* With measurable and inoperable brain metastasis,
* Without meningeal carcinomatosis ,
* ECOG performance status ≤ 2,
* No previous treatment with angiogenesis inhibitors less than 3 months before inclusion,
* No chemotherapy and/or immunotherapy less than 3 weeks before treatment,
* No contra-indication to bevacizumab,
* No proteinuria with urine dipstick for proteinuria \> 2+
* Blood sample ≤ 7 days before inclusion:
* Hemoglobin ≥ 10 G/100 ml
* Neutrophils count ≥ 1500 /mm3
* Platelets ≥ 100 000 /mm3
* Normal coagulation test: INR ≤ 1,5 ET TCA ≤ 1,5 x LSN 7 days before inclusion
* A written informed consent must be obtained.

Exclusion Criteria:

* Haemorrhagic brain metastasis,
* Uncontrolled hypertension (systolic \> 150 mm Hg and/or diastolic \> 100 mm Hg). Patients with high initial blood pressure are eligible if entry criteria are met after initiation or adjustment of antihypertensive medication,
* Prior brain radiation therapy
* Concomitant anticoagulant treatment
* Significant surgical procedure less than 28 days before inclusion (1 day if minor surgical act)
* Significant cardio-vascular disease, eg:
* Cerebral vascular thrombosis/haemorrhage or myocardial infarction \<6 months
* Congestive heart failure \> 2 NYHA
* Uncontrolled coronary disease
* Prior venous and/or arterial thrombosis \< 6 months before inclusion
* Severe concurrent uncontrolled medical disease,
* Any psychiatric disorder that might prevent the subject from completing the treatment or interfere with the interpretation of the study results,
* Pregnancy or breast feeding
* Individual deprived of liberty or placed under the authority of a tutor.